Claus Moller decreased its stake in Ebix Inc (EBIX) by 0.9% based on its latest 2016Q4 regulatory filing with the SEC. The hedge fund run by Claus Moller held 1.62M shares of the technology company at the end of 2016Q4, valued at $92.42 …
1492 Capital Management Llc sold 14,461 shares as Ligand Pharmaceuticals Inc. (LGND)’s stock rose 7.66%. The …
The stock spiked 7.8% last month and is up 24.96 this year. They expect $1.42 earnings per share, up 1.43% or $0.02 from last year's $1.4 per share. Ligand Pharmaceuticals now has $2.61 billion valuation. Ligand Pharmaceuticals …
Ligand Pharmaceuticals Incorporated (LGND) traded on unusually high volume on Aug. 17, as the stock lost 0.72% to close at $126.62. On the day, Ligand Pharmaceuticals Incorporated saw 332,255 shares trade hands on 2,245 trades. …
Ligand Pharmaceuticals Incorporated LGND reported second-quarter 2017 earnings of 54 cents per share (including the after-tax impact of stock-based …
Deutsche Bank AG reiterated their hold rating on shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) in a research note released on Monday, July 17th. They currently have a $103.00 price objective on the biotechnology …
Follow Ligand on Twitter @Ligand_LGND. Forward-Looking Statements This news release contains ... The failure to …
Myovant Sciences Ltd. Price and EPS Surprise Myovant Sciences Ltd. Price and EPS Surprise | Myovant Sciences Ltd. Quote A better-ranked stock in the …
SmarTrend identified an Uptrend for Ligand Pharm (NASDAQ:LGND) on March 10th, 2017 at $108.63. In approximately 5 months, Ligand Pharm has returned 16.88% as of today's recent price of $126.97. Over the past year, Ligand Pharm …